AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
"You Hurled Me Into the Depths, Into the Very Heart of the Seas" is the second episode of the fourth season of the American dark comedy crime television series The Righteous Gemstones. It is the 29th overall episode of the series and was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. It was released on HBO on March 16, 2025, and also was available on Max on the same date. The series follows a family of televangelists and megachurch pastors led by widowed patriarch Eli Gemstone. The main focus is Eli and his immature children, Jesse, Kelvin and Judy, all of whom face challenges in their lives. The series depicts the family's past and scandals, which unleash consequences. In the episode, the Gemstones try to locate a missing Elijah for a telethon. According to Nielsen Media Research, the episode was seen by an estimated 0.264 million household viewers and gained a 0.05 ratings share among adults aged 18–49. The episode received mostly positive reviews from critics, who praised its humor, performances and character development.
==== Ernst & Young Global Limited ==== A former partner of the UK-based accounting firm Ernst & Young, Amjad Rihan was ousted after he attempted to report the money laundering and gold smuggling efforts of Dubai-based firm Kaloti Jewellery International. Rihan had claimed that "Kaloti was knowingly dealing in gold bullion smuggled out of Morocco". However, after he reported the issue, the Dubai government body, DMCC, attempted to put unnecessary pressure on him and his firm. In 2021, Ernst & Young withdrew an eight-year-long legal fight against Rihan asking a compensation of $10.8 million from him.
X-linked chronic granulomatous disease (CGD) autosomal recessive cytochrome b-negative CGD autosomal recessive cytochrome b-positive CGD type I autosomal recessive cytochrome b-positive CGD type II atypical granulomatous disease
CG Cosmogenic nuclide. DP Naturally occurring decay product (of thorium-232, uranium-238, or uranium-235), including products of neutron reactions other than fission. ESS Present in the early Solar System (first few million years), but extinct now as a primordial nuclide. Inherently overlaps with cosmogenic nuclides. FP Nuclear fission product , may occur naturally from spontaneous fission. IM Industry or medically used radionuclide.
Sources: en.wikipedia.org
The cephalic phase: Thirty percent of the total gastric acid secretions to be produced is stimulated by anticipation of eating and the smell or taste of food. This signalling occurs from higher centres in the brain through the vagus nerve (Cranial Nerve X). It activates parietal cells to release acid and ECL cells to release histamine. The vagus nerve (CN X) also releases gastrin releasing peptide onto G cells. Finally, it also inhibits somatostatin release from D cells. The gastric phase: About sixty percent of the total acid for a meal is secreted in this phase. Acid secretion is stimulated by distension of the stomach and by amino acids present in the food. The intestinal phase: The remaining 10% of acid is secreted when chyme enters the small intestine, and is stimulated by small intestine distension and by amino acids. The duodenal cells release entero-oxyntin which acts on parietal cells without affecting gastrin.
== Possible problems == The maximum pressure rating of a metering pump is actually the top of the discharge pressure range the pump is guaranteed to pump against at a reasonably controllable flow rate. The pump itself is a pressurizing device often capable of exceeding its pressure rating, although not guaranteed to. For this reason, if there is any stop valve downstream of the pump, a pressure relief valve should be placed in between to prevent overpressuring of the tubing or piping line in case the stop valve is inadvertently shut while the pump is running. The relief valve setting should be below the maximum pressure rating that the piping, tubing, or any other components there could withstand. Liquids are only very slightly compressible. This property of liquids lets metering pumps discharge liquids at high pressure. Since a liquid can be only slightly compressed during a discharge stroke, it is forced out of the pump head. Gases are much more compressible. Metering pumps are not good at pumping gases. Sometimes, a metering or similar pump has to be primed before operation, i. e. the pump head filled with the liquid to be pumped. When gas bubbles enter a pump head, the compression motion compresses the gas but has a hard time forcing it out of the pump head. The pump may stop pumping liquid with gas bubbles in the pump head even though mechanically the pump is going through the motions, repeatedly compressing and decompressing the bubbles. To prevent this type of "vapor lock", chromatography solvents are often degassed before pumping.
== Chemical classes == As hormones are defined functionally, not structurally, they may have diverse chemical structures. Hormones occur in multicellular organisms (plants, animals, fungi, brown algae, and red algae). These compounds occur also in unicellular organisms, and may act as signaling molecules however there is no agreement that these molecules can be called hormones.
Sources: en.wikipedia.org
By binding the Fc portion of antibodies, protein A renders them inaccessible to the opsonins, thus impairing phagocytosis of the bacteria via immune cell attack. Protein A facilitates the adherence of S. aureus to human von Willebrand factor (vWF)-coated surfaces, thus increasing the bacteria's infectiousness at the site of skin penetration. Protein A can inflame lung tissue by binding to tumor necrosis factor 1 (TNFR-1) receptors. This interaction has been shown to play a key role in the pathogenesis of staphylococcal pneumonia. Protein A has been shown to cripple humoral (antibody-mediated) immunity which in turn means that individuals can be repeatedly infected with S. aureus since they cannot mount a strong antibody response. Protein A has been shown to promote the formation of biofilms both when the protein is covalently linked to the bacterial cell wall as well as in solution. Protein A helps inhibit phagocytic engulfment and acts as an immunological disguise. Higher levels of protein A in different strains of S. aureus have been associated with nasal carriage of this bacteria. Mutants of S. aureus lacking protein A are more efficiently phagocytosed in vitro, and mutants in infection models have diminished virulence.
=== Inhibition of apoptosis === One of the ways cell apoptosis is activated is by release of cytochrome c from the mitochondria into cytosol. A study has shown that cells are able to protect themselves from apoptosis by blocking the release of cytochrome c using Bcl-xL. Another way that cells can control apoptosis is by phosphorylation of Tyr48, which turns cytochrome c into an anti-apoptotic switch.
=== Metal–organic framework-based nano-adsorbent remediation === Researchers have suggested that metal–organic frameworks (MOFs) and MOF-based nano-adsorbents (MOF-NAs) could be used in the removal of certain CEC, such as pharmaceuticals and personal care products, especially in wastewater treatment. Widespread use of MOF-based nano-adsorbents has yet to be implemented due to complications created by the vast physicochemical properties that CEC contain. The removal of CEC largely depends on the structure and porosity of the MOF-NAs and the physicochemical compatibility of both the CEC and the MOF-NAs. If a CEC is not compatible with the MOF-NA, then particular functional groups can be chemically added to increase compatibility between the two molecules. The addition of functional groups causes the reactions to rely on other chemical processes and mechanisms, such as hydrogen bonding, acid-base reactions, and complex electrostatic forces. MOF-based nano-adsorbent remediation heavily relies on water-qualities, such as pH, in order for the reaction to be executed efficiently. MOF-NA remediation can also be used to efficiently remove other heavy metals and organic compounds in wastewater treatment.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.